Guanfacine to Improve Substance Use Outcomes in Women
Addictive Behaviors | Mental Health & Behavioral Research
What is the purpose of this trial?
This study proposes to extend previous Phase I experimental work to address the following specific aims: (1) assess GUA's target engagement of drug craving and cognitive flexibility in a laboratory challenge session and in a 10-week outpatient clinical study, (2) demonstrate target validation by showing that reduced drug craving and improved cognitive flexibility will predict lower drug use outcomes during the 10-week clinical trial in SUD women, and finally, (3) evaluate data replication and scalability of GUA target effects across two clinical sites (Yale and SUNY-Stony Brook).
- Ages18 years - 55 years
- GenderFemale only
- Trial withNational Institute on Drug Abuse (NIDA)
- Start Date09/16/2019
- End Date06/29/2021
- Last Updated10/25/2019
- Study HIC#2000025416